Articles tagged with: Pomalidomide
Celgene announced this morning that it plans to submit an application for the approval of pomalidomide for relapsed and refractory multiple myeloma to the U.S. Food and Drug Administration (FDA) during the first quarter of 2012.
In addition, the company said that it plans to submit a similar application to the European Medicines Agency (EMA) during the first half of this year.
The updated submission timeline means that pomalidomide could be approved for use in the United States and in Europe by the end of this year.
Celgene’s announcement was made …
Pomalidomide was one of the potential new myeloma treatments in the spotlight at the 2011 meeting of the American Society of Hematology (ASH) held earlier this month.
The consensus is that the drug, a chemical relative of thalidomide and Revlimid, performed well during its time on the stage.
Most of these presentations examined pomalidomide’s efficacy and safety as a potential treatment for relapsed and refractory myeloma …
What were the myeloma-related “hidden gems” of the recent American Society of Hematology (ASH) annual meeting, which ended two weeks ago?
The Beacon asked exactly this question of its Medical Advisors — the myeloma specialists who generously share their knowledge and expertise in the Beacon’s myeloma discussion forum.
And the responses from the Advisors were surprising.
Surprising, because they were so similar.
The three Advisors who responded to the Beacon’s question independently picked the same “hidden gem” – specifically, the research presented at the meeting showing that …
It has been ten days since the 2011 annual meeting of the American Society of Hematology (ASH) came to a close.
In this and The Beacon’s next article about the meeting, however, the perspective changes a bit.
The focus shifts to the bigger picture — to questions like: “What was the impact of the …
The afternoon sessions of the third day of the American Society of Hematology (ASH) 2011 annual meeting in San Diego were just as awash with myeloma-related presentations as were the morning sessions.
Many of the afternoon sessions were devoted to two particular potential new myeloma treatments: carfilzomib and pomalidome.
Those presentations will be covered in this article, while presentation from the afternoon sessions that were about other new therapies will be summarized in the final daily update for the meeting’s third day.